Get 15% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!

What key factors are powering the surge in the aurora kinase b market right now?

In recent years, the market size for aurora kinase b has expanded swiftly. It is projected to balloon from $1.14 billion in 2024 to $1.27 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the historic period include heightened demand for targeted cancer treatments, a global surge in cancer prevalence, escalated investments in precision medicine, an increasing number of clinical trials, and enhanced government funding for cancer research.

How fast Is the aurora kinase b market expected to grow, and what’s its future value?

In the coming years, a swift expansion is anticipated in the market size of aurora kinase b, increasing to $1.99 billion in 2029, with a compound annual growth rate (CAGR) of 11.8%. The anticipated growth during the forecasted span can be credited to an increase in investments in cutting-edge cancer therapies, the surge in drug-resistant cancer cases, escalated research and development activities, intensifying demand for combination therapies, and the rising prevalence of solid tumors. Key trends projected for the forecast period involve technological innovations, precision medicine, new treatment methods, data analytics, and novel therapies.

Get your aurora kinase b market report here!

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

What are the leading drivers of growth in the aurora kinase b market?

The escalation of cancer prevalence is predicted to drive the expansion of the aurora kinase B market in the future. Cancer, which comprises a variety of diseases characterized by uncontrolled and abnormal cell growth that can infiltrate nearby tissues and spread to different body regions, is on the rise for a variety of reasons, including an aging population, lifestyle modifications, environmental risk factors, and enhanced diagnostic and detection methods. Aurora kinase B, crucial to the process of mitosis, becomes overexpressed, which can lead to chromosomal instability and the progression of cancer. As it is involved in tumor cell division, it is commonly a target in cancer treatments. For example, the World Health Organization, a Switzerland-based international organization, reported in February 2024 that an estimated 20 million new cancer cases arose in 2022, resulting in 9.7 million deaths. By 2050, the number of new cancer cases is projected to surpass 35 million, a 77% increase from 2022 figures. Consequently, the escalating prevalence of cancer is fueling the growth of the aurora kinase B market.

What are the key segments defining the aurora kinase b market?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Who are the key players steering the development of the aurora kinase b market?

Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

What emerging trends are influencing the growth of the aurora kinase b market?

Noteworthy firms in the aurora kinase B market are inventing unique products such as aurora kinase inhibitors, aimed at targeting and disrupting key cellular division processes. Aurora kinase inhibitors are medications conceived to impede the functions of Aurora kinases, vital for cell division, thus curbing cancer cell propagation and potentially minimizing tumor expansion. For instance, in June 2023, a biotech company based in the UK, Ellipses Pharma, received approval from the U.S. Food and Drug Administration (FDA) for its product EP0042, a twin FLT-3 and Aurora kinase inhibitor. EP0042 is currently under development as a remedy for acute myeloid leukemia (AML), functioning as an inhibitor that targets both FLT3 and Aurora kinase. This strategy is exclusively designed for AML sufferers who have developed immunity against FLT3 inhibitors. Studies have shown that a combined obstruction of FLT3 and Aurora kinase can circumvent acquired resistance to selective FLT3 inhibition both in vitro and in vivo.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20496

Which regions are most influential in expanding the aurora kinase b market?

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: